Search Results - "Sahraian, M"

A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients by Pazhouhandeh, M., Sahraian, M.‐A., Siadat, S. D., Fateh, A., Vaziri, F., Tabrizi, F., Ajorloo, F., Arshadi, A. K., Fatemi, E., Piri Gavgani, S., Mahboudi, F., Rahimi Jamnani, F.

“…Summary Identification of autoimmune processes and introduction of new autoantigens involved in the pathogenesis of multiple sclerosis (MS) can be helpful in…”
Get full text

Black holes in multiple sclerosis: definition, evolution, and clinical correlations by Sahraian, M. A., Radue, E.-W., Haller, S., Kappos, L.

“…Sahraian MA, Radue E‐W, Haller S, Kappos L. Black holes in multiple sclerosis: definition, evolution, and clinical correlations.
Acta Neurol Scand: 2010: 122:…”
Get full text

B cells in multiple sclerosis therapy—A comprehensive review by Rahmanzadeh, R., Weber, M. S., Brück, W., Navardi, S., Sahraian, M. A.

“…For decades, B cells were ignored in multiple sclerosis (MS) pathogenesis, and the disease was always regarded as a T cell‐mediated disorder. Recent evidence…”
Get full text

Burden of neurodegenerative diseases in the Eastern Mediterranean Region, 1990–2016: findings from the Global Burden of Disease Study 2016 by Fereshtehnejad, S.‐M., Vosoughi, K., Heydarpour, P., Sepanlou, S. G., Farzadfar, F., Tehrani‐Banihashemi, A., Malekzadeh, R., Sahraian, M. A., Vollset, S. E., Naghavi, M., Vos, T., Feigin, V., Murray, C., Mokdad, A. H., Moradi‐Lakeh, M.

“…Background and purpose The Eastern Mediterranean Region (EMR) is experiencing a demographic shift towards rapid aging at a time of political unrest. We aimed…”
Get full text

Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines by Yamout, B., Sahraian, M., Bohlega, S., Al-Jumah, M., Goueider, R., Dahdaleh, M., Inshasi, J., Hashem, S., Alsharoqi, I., Khoury, S., Alkhawajah, M, Koussa, S., Al Khaburi, J., Almahdawi, A., Alsaadi, T., Slassi, E., Daodi, S, Zakaria, M., Alroughani, R.

“…•Diagnostic and treatment algorithms need revision and updating.•MS diagnosis incorporates clinical and paraclinical findings.•The differential diagnostic…”
Get full text

Smoking and worsening disability in multiple sclerosis: A meta‐analysis by Heydarpour, P., Manouchehrinia, A., Beiki, O., Mousavi, S. E., Abdolalizadeh, A., ‐Lakeh, M. Moradi, Sahraian, M. A.

“…Objectives Multiple sclerosis (MS) is a chronic demyelinating disorder affecting young adults. Environmental factors and lifestyle behaviors are pivotal in MS…”
Get full text

Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis by Sahraian, M. A., Radue, E.-W., Eshaghi, A., Besliu, S., Minagar, A.

“…Progressive multifocal leukoencephalopathy (PML) is an uncommon and often fatal demyelinating disease of human central nervous system, which is caused by…”
Get full text

Late-onset neuromyelitis optica spectrum disorder: A case series from Iran by Ghadiri, F., Eskandarieh, S., Sahraian, M.A., Azimi, A., Moghadasi, A.N.

“…Neuromyelitis optica spectrum disorder (NMOSD) is a disabling autoimmune disease of the central nervous system that can start at ages of 50 or more, when it is…”
Get full text

Tumefactive demyelinating lesions after initiating fingolimod in patient with multiple sclerosis: A case report by Navardi, S., Sahraian, M.A., Naser Moghadasi, A.

Get full text

Relapsing Neuromyelitis Optica: demographic and clinical features in Iranian patients by Sahraian, M. A., Moinfar, Z., Khorramnia, S., Mohammad Ebrahim, M.

“…Background:  Neuromyelitis Optica (NMO) is a severe inflammatory demyelinating disease of the central nervous system with distinguishing features from multiple…”
Get full text

Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study by Abbasi Kasbi, Naghmeh, Ghadiri, F., Sahraian, M. A., Nahayati, M. A., Moghadasi, A. Naser, Langroodi, H. Ghalyanchi, Poursadeghfard, M., Hosseini, S., Heidari, H., Baghbanian, S. M., Kamali, H., Ameli, Z., Shahmohammadi, S., Navardi, S.

“…Background Ocrelizumab is a humanized antiCD20, thought to be a highly effective disease-modifying therapy (DMT). Its most frequent adverse effects are…”
Get full text

Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control study by Harirchian, M. H., Tekieh, A. H., Modabbernia, A., Aghamollaii, V., Tafakhori, A., Ghaffarpour, M., Sahraian, M. A., Naji, M., Yazdanbakhsh, M.

“…Background and purpose:  Fibroblast growth factor‐2 (FGF‐2) and platelet‐derived growth factor‐A (PDGF‐AA) are potent modulators of oligodendrocytes, the main…”
Get full text

A multicenter multinational study to evaluate different aspects of the relationship between MS and pregnancy by Gozubatik-Celik, R.G., Sen, S., Tay, B., Alroughani, R., Zakaria, M., Moghadasi, A.N., Terzi, M., Koseoglu, M., Efendi, H., Soysal, A., Ozturk, M., Akinci, Y., Kaya, Z.E., Saip, S., Siva, A., Sahraian, M., Gonen, M., Altintas, A.

“…•This retrospective international multicenter study emerges as the first in this region to gather data regarding the effect of pregnancy on MS and the effect…”
Get full text

Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines by Yamout, B., Al-Jumah, M., Sahraian, M.A., Almalik, Y, Khaburi, J. Al, Shalaby, N., Aljarallah, S, Bohlega, S., Dahdaleh, M., Almahdawi, A., Khoury, S.J., Koussa, S., Slassi, E., Daoudi, S, Aref, H., Mrabet, S., Zeineddine, M., Zakaria, M., Inshasi, J., Gouider, R., Alroughani, R.

“…•2019 MENACTRIMS diagnostic and treatment algorithms need revision and updating.•Appropriate selection of MS therapies is critical to maximize patient…”
Get full text

Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS) by Yamout, B., Alroughani, R., Al-Jumah, M., Goueider, R., Dahdaleh, M., Inshasi, J., Hashem, S., Alsharoqi, I., Sahraian, M., Khoury, S., Alkawi, Z., Koussa, S., Zakaria, M., Al Khaburi, J., Alsaadi, T., Bohlega, S.

“…Abstract With evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS, most current diagnostic and treatment algorithms need…”
Get full text

Concomitant multiple sclerosis and idiopathic thrombocytopenic purpura by Sahraian, M. A., Eshaghi, A.

Get full text

Avascular necrosis of the femoral head in multiple sclerosis: report of five patients by Sahraian, M. A., Yadegari, S., Azarpajouh, R., Forughipour, M.

“…Osteonecrosis of the femoral head is a severe complication of corticosteroids, which may lead to more disability in multiple sclerosis (MS) patients because of…”
Get full text

Evaluation of apoptosis-related genes; Fas (CD94), FasL (CD178) and TRAIL polymorphisms in Iranian multiple sclerosis patients by Mohammadzadeh, A, Pourfathollah, A.A, Sahraian, M.A, Behmanesh, M, Daneshmandi, S, Moeinfar, Z, Heidari, M

“…Abstract Multiple sclerosis (MS) is a central nervous system (CNS) demyelinating disease characterized by a relapsing–remitting course leading to progressive…”
Get full text

Significant increase in the prevalence of MS in Iran by Izadi, S, Nikseresht, A, Sharifian Dorche, M, Sahraian, M

Get full text

Burden of musculoskeletal disorders in Iran during 1990–2017: estimates from the Global Burden of Disease Study 2017 by Shahrezaee, M., Keshtkari, S., Moradi-Lakeh, M., Abbasifard, M., Alipour, V., Amini, S., Arabloo, J., Arzani, A., Bakhshaei, M., Barzegar, A., Bijani, A., Dianatinasab, M., Eskandarieh, S., Gheshlagh, R. Ghanei, Ghashghaee, A., Heidari-Soureshjani, R., Irvani, S.S.N., Lahimchi, A., Maleki, S., Manafi, N., Manafi, A., Mansournia, M. A.., Mohammadian-Hafshejani, A., Bandpei, M. A. Mohseni, Moradzadeh, R., Naderi, M., Pakshir, K., Rafiei, A., Rashedi, V., Rezaei, N., Rezapour, A., Sahraian, M. A., Shahabi, S., Shamsi, M., Soheili, A., Soroush, A., Zamani, M., Mohajer, B., Farzadfar, F.

“…Summary Musculoskeletal diseases (MSDs) are the leading cause of disability and facing them demands updated reports on their burden for efficient policymaking…”
Get full text